Medical Industry Feature

ReachMD
  • 4.0 (1)
  • Science
  • Updated Daily

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

  1. 5d ago

    The Patient You Might Be Missing: Severe Hypertriglyceridemia in Clinical Practice

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erin D. Michos, MD, MHS Severe hypertriglyceridemia (sHTG) affects more than 3 million people, but it often flies under the clinical radar.1-3 When triglycerides are at or above a 500 mg/dL threshold, it’s no longer just an isolated lab value—it’s a level of hypertriglyceridemia where the clinical implications change, and where a more careful evaluation for underlying causes and risk becomes important.4 That’s why Dr. Charles Turck sits down with Dr. Erin Michos to discuss what sHTG is, why it’s so important to identify, and how we can effectively manage this condition to improve patients’ overall health and reduce complication risk. Dr. Erin Michos is a Professor of Medicine, Director of Women’s Cardiovascular Health, and Associate Director of Preventive Cardiology at Johns Hopkins University School of Medicine. References: Saadatagah S, Larouche M, Naderian M, et al. Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology. Am J Prev Cardiol. 2025;22:100978. doi:10.1016/j.ajpc.2025.100978 Sanchez RJ, Ge W, Wei W, Ponda MP, Rosenson RS. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids Health Dis. 2021;20(1):72. doi:10.1186/s12944-021-01488-8 Sikora Kessler A, Baum SJ, Kutrieb E, et al. Rates …

  2. Aug 5

    Pediatric Influenza: Risks, Realities, and Prevention

    Host: Jennifer Caudle, DO, FACOFP Guest: Laura Sass, MD Pediatric influenza carries a significant clinical burden, with children under four experiencing one of the highest rates of influenza-related illness, healthcare visits, and hospitalization.1,2 Seasonal influenza vaccination remains an evidence-based strategy to reduce illness and severe outcomes, with a well-established safety profile and continued support from leading U.S. health authorities.3,4 Joining Dr. Jennifer Caudle to share her perspective on the importance of influenza vaccination in children is Dr. Laura Sass. Dr. Laura Sass is an Associate Professor of Pediatrics at Eastern Virginia Medical School and a board-certified Pediatric Infectious Diseases specialist at Children's Hospital of The King's Daughters. References: US Centers for Disease Control and Prevention (CDC). Laboratory-confirmed influenza hospitalizations. Accessed March 31, 2026. https://gis.cdc.gov/grasp/fluview/FluHospChars.html#virusTypeDiv. US Centers for Disease Control and Prevention (CDC). Influenza Activity in the United States during the 2024–25 Season and Composition of the 2025–26 Influenza Vaccine. Accessed March 31, 2026. https://www.cdc.gov/flu/whats-new/2025-2026-influenza-activity.html. US Centers for Disease Control and Prevention (CDC). Flu Vaccine Effectiveness for Children and Older Adults. Updated August 14. 2024. Accessed March 31, 2026. https://www.cdc.gov/flu-vaccines-work/risk-groups/index.html. Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2025-2026: Policy Statement. Pediatrics. 2025;156(6)doi:10.1542/peds.2025-073620

  3. Aug 3

    Secondary IOL Surgery Is Unprofitable Under Current Medicare Reimbursement Rates. Now What?

    Host: Maria Berrocal How much money are retina surgeons losing on secondary IOL procedures? In this episode of Clinical Minute: Retina, host Maria Berrocal, MD, speaks with Nimesh "Nemo" Patel, MD, whose research uncovered how many cases are unprofitable under current Medicare reimbursement rates, and assess how much cash surgeons burn per case. Dr. Patel discusses the implications for patient access, the advocacy efforts underway through the ASRS Health Economics Committee, and why closing the gap between reimbursement and operative complexity will require direct engagement with policymakers.

  4. Jul 20

    Cerebral Organoid Model Transforms Glioblastoma Research

    Guest: Howard Fine, M.D. Dr. Howard Fine, a neuro-oncologist at NewYork-Presbyterian and Weill Cornell Medicine, discusses how a new approach to glioblastoma research may expand treatment options and advance precision oncology. His preclinical model, GLICO, uses cerebral organoids, or mini brains, to create a more accurate representation of glioblastoma tumor biology. Through an advanced, high-throughput drug-screening system that Dr. Fine and his team developed, they can screen hundreds of GLICOs against various drug regimens to identify personalized glioblastoma therapies—with the ultimate goal of extending patient survival for one of the most lethal cancers. © 2026 NewYork-Presbyterian

  5. Jul 14

    Clinical Features and Outcomes of IOFB Removal

    What do large registry data reveal about outcomes after intraocular foreign body removal, and how should those findings shape surgical planning and patient counseling? In this episode of New Retina Radio Journal Club with VBS, Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, on a 2025 IRIS Registry analysis of nearly 4,800 eyes. The group reviews the delayed timeline of visual recovery, the risk of late complications, and practical guidance on staging surgical intervention and setting realistic expectations in complex trauma cases.

  6. Jul 6

    Socioeconomic Determinants and Outcomes in Proliferative Sickle Retinopathy

    Host: Maria Berrocal Guest: Audina Berrocal, MD Does socioeconomic status influence outcomes in proliferative sickle retinopathy? In this episode of Clinical Minute: Retina, host Maria Berrocal, MD, speaks with Audina "Nina" Berrocal, MD, of Bascom Palmer Eye Institute, who published a retrospective review of more than 100 patients with proliferative sickle retinopathy. They explore whether the integrated care model at Bascom Palmer may account for results that don't translate to other parts of the country. The conversation also touches on newborn screening programs in Florida and the importance of sickle cell centers in high-incidence communities.

  7. Jun 17

    Redefining Durability in Wet AMD: Insights from the SOL‑1 Superiority Trial

    Host: Priya Vakharia, MD Guest: Andrew Moshfeghi, MD The SOL-1 Phase 3 superiority trial compared the efficacy and safety of the investigational product OTX-TKI (axitinib intravitreal hydrogel) with aflibercept 2 mg. The primary endpoint was proportion of subjects who maintained visual acuity, defined as 15 Early Treatment Diabetic Retinopathy Study letters of best-corrected visual acuity loss from baseline at Week 36. Based on the findings, SOL-1 met its primary endpoint and demonstrated a statistically significant high proportion of subjects maintained visual acuity with OTX-TKI vs. aflibercept 2 mg at Week 36. OTX-TKI demonstrated stability in vision and anatomic outcomes through 36 weeks, with evidence of extended durability and delayed need for rescue therapy. This could contribute to the goal of maintaining disease control in wet AMD. OTX-TKI was generally well tolerated through Week 52. Ocular adverse events were reported in 52.9% of OTX-TKI-treated subjects vs. 33.7% of aflibercept-treated subjects. There were no treatment-related serious adverse events (SAEs) and no cases of retinal vasculitis. The most common AEs reported in OTX-TKI subjects were vitreous floaters (12.4%), cataract (7.1%) and conjunctival hemorrhage (6.5%). To learn more about the SOL-1 trial design, findings, and implications for care, tune in to hear Dr. Priya Vakharia speak with Dr. Andrew Moshfeghi. Reference: Heier …

  8. May 19

    Expandable Cages Enhance Minimally Invasive Spinal Fusion

    Guest: Ibrahim Hussain, M.D. Neurological spine surgeon Dr. Ibrahim Hussain explains how expandable cages are being used in minimally invasive transforaminal lumbar interbody fusions to optimize patient outcomes. These cages can be inserted with a very low profile to restore height and lordosis, and enable a faster recovery. At Och Spine at NewYork-Presbyterian, surgeons are pursuing innovative solutions to provide a better quality of life for patients with degenerative disc disease and other spine conditions. © 2026 NewYork-Presbyterian

See All (38)

About

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Information

  • Creator
    ReachMD
  • Years Active
    2014 - 2026
  • Episodes
    38
  • Rating
    Clean
  • Copyright
    © Copyright 2026 ReachMD. All rights reserved.
  • Show Website
    Medical Industry Feature

More From ReachMD